BioMarin Pharmaceutical Inc. (BMRN)
NASDAQ: BMRN · Real-Time Price · USD
65.66
+0.66 (1.02%)
Dec 20, 2024, 4:00 PM EST - Market closed
BioMarin Pharmaceutical Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 2,753 | 2,419 | 2,096 | 1,846 | 1,860 | 1,704 | Upgrade
|
| Revenue Growth (YoY) | 19.14% | 15.42% | 13.53% | -0.76% | 9.18% | 14.27% | Upgrade
|
| Cost of Revenue | 1,312 | 1,262 | 1,133 | 1,099 | 1,152 | 1,074 | Upgrade
|
| Gross Profit | 1,441 | 1,158 | 962.76 | 746.97 | 708.07 | 629.58 | Upgrade
|
| Selling, General & Admin | 1,033 | 923.29 | 831.01 | 759.38 | 737.67 | 680.92 | Upgrade
|
| Operating Expenses | 1,115 | 985.5 | 893.8 | 821.28 | 799.83 | 734.43 | Upgrade
|
| Operating Income | 326.41 | 172.1 | 68.96 | -74.32 | -91.76 | -104.86 | Upgrade
|
| Interest Expense | -16.19 | -17.34 | -15.97 | -15.34 | -29.31 | -23.46 | Upgrade
|
| Interest & Investment Income | 75.25 | 58.34 | 18.03 | 10.48 | 16.61 | 22.75 | Upgrade
|
| Other Non Operating Income (Expenses) | 21.88 | 13.96 | -2.05 | 11.85 | 6.59 | 6.36 | Upgrade
|
| EBT Excluding Unusual Items | 407.35 | 227.06 | 68.98 | -67.32 | -97.87 | -99.21 | Upgrade
|
| Merger & Restructuring Charges | - | - | -23 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | - | -12.6 | - | - | 0.55 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 10 | - | 108 | - | 52.82 | 25 | Upgrade
|
| Asset Writedown | -14 | -14 | - | - | - | - | Upgrade
|
| Other Unusual Items | -11.9 | -11.9 | -4.4 | -8.03 | -4.5 | -20.6 | Upgrade
|
| Pretax Income | 391.45 | 188.56 | 149.58 | -75.35 | -49 | -94.81 | Upgrade
|
| Income Tax Expense | 69.16 | 20.92 | 8.02 | -11.27 | -903.03 | -70.96 | Upgrade
|
| Net Income | 322.29 | 167.65 | 141.56 | -64.08 | 854.03 | -23.85 | Upgrade
|
| Net Income to Common | 322.29 | 167.65 | 141.56 | -64.08 | 854.03 | -23.85 | Upgrade
|
| Net Income Growth | 119.21% | 18.43% | - | - | - | - | Upgrade
|
| Shares Outstanding (Basic) | 189 | 188 | 185 | 183 | 181 | 179 | Upgrade
|
| Shares Outstanding (Diluted) | 193 | 192 | 189 | 183 | 192 | 179 | Upgrade
|
| Shares Change (YoY) | 0.93% | 1.39% | 3.34% | -4.60% | 7.06% | 1.00% | Upgrade
|
| EPS (Basic) | 1.70 | 0.89 | 0.76 | -0.35 | 4.72 | -0.13 | Upgrade
|
| EPS (Diluted) | 1.68 | 0.87 | 0.75 | -0.35 | 4.50 | -0.13 | Upgrade
|
| EPS Growth | 118.12% | 16.00% | - | - | - | - | Upgrade
|
| Free Cash Flow | 319.89 | 62.57 | 54.94 | 208.96 | -28.95 | -96.76 | Upgrade
|
| Free Cash Flow Per Share | 1.66 | 0.33 | 0.29 | 1.14 | -0.15 | -0.54 | Upgrade
|
| Gross Margin | 52.35% | 47.85% | 45.93% | 40.46% | 38.06% | 36.95% | Upgrade
|
| Operating Margin | 11.86% | 7.11% | 3.29% | -4.03% | -4.93% | -6.15% | Upgrade
|
| Profit Margin | 11.71% | 6.93% | 6.75% | -3.47% | 45.90% | -1.40% | Upgrade
|
| Free Cash Flow Margin | 11.62% | 2.59% | 2.62% | 11.32% | -1.56% | -5.68% | Upgrade
|
| EBITDA | 426.09 | 276.48 | 170.93 | 33.72 | 13.41 | 0.44 | Upgrade
|
| EBITDA Margin | 15.48% | 11.43% | 8.15% | 1.83% | 0.72% | 0.03% | Upgrade
|
| D&A For EBITDA | 99.68 | 104.39 | 101.97 | 108.04 | 105.17 | 105.3 | Upgrade
|
| EBIT | 326.41 | 172.1 | 68.96 | -74.32 | -91.76 | -104.86 | Upgrade
|
| EBIT Margin | 11.86% | 7.11% | 3.29% | -4.03% | -4.93% | -6.15% | Upgrade
|
| Effective Tax Rate | 17.67% | 11.09% | 5.36% | - | - | - | Upgrade
|
| Revenue as Reported | 2,753 | 2,419 | 2,096 | 1,846 | 1,860 | 1,704 | Upgrade
|
| Advertising Expenses | - | 27.8 | 25.2 | 30.2 | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.